The main issue for the company is that Amgen’s rival KRAS inhibitor Lumykras (sotorasib) has already been given conditional approval in the EU, so the CHMP considers that Mirati was unable to ...
Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...
Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is understandably excited by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback